Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

Assessment of the relative potency of emtricitabine and lamivudine.

Schinazi RF.

J Acquir Immune Defic Syndr. 2003 Oct 1;34(2):243-5; author reply 245-6. No abstract available.

PMID:
14526216
2.

Relative anti-HIV-1 efficacy of lamivudine and emtricitabine in vitro is dependent on cell type.

Hazen R, Lanier ER.

J Acquir Immune Defic Syndr. 2003 Mar 1;32(3):255-8.

PMID:
12626884
3.

Differential impact of thymidine analogue mutations on emtricitabine and lamivudine susceptibility.

Ross LL, Parkin N, Gerondelis P, Chappey C, Underwood MR, St Clair MH, Lanier ER.

J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):567-70.

PMID:
17075395
4.

Emtricitabine compared with lamivudine may preserve future therapeutic options in HIV-1-infected children.

Frange P, Blanche S, Chaix ML.

J Antimicrob Chemother. 2013 Nov;68(11):2694-5. doi: 10.1093/jac/dkt215. Epub 2013 Jun 5. No abstract available.

PMID:
23743089
5.
6.

In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine.

Borroto-Esoda K, Vela JE, Myrick F, Ray AS, Miller MD.

Antivir Ther. 2006;11(3):377-84.

PMID:
16759055
7.

Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART.

Palacios R, Hidalgo C, Ríos MJ, Rivero A, Muñoz L, Lozano F, Gutiérrez-Ravé V, Gálvez MC, del Arco A, Santos J.

Eur J Clin Microbiol Infect Dis. 2009 Apr;28(4):399-402. doi: 10.1007/s10096-008-0636-x. Epub 2008 Oct 8.

PMID:
18841401
8.

Use of tenofovir disoproxil fumarate and emtricitabine combination in HIV-infected patients.

Gazzard BG.

Expert Opin Pharmacother. 2006 Apr;7(6):793-802. Review.

PMID:
16556093
9.

Letter to the editor: Hypersensitivity to lamivudine and emtricitabine.

Loulergue P, Mir O.

Curr HIV Res. 2012 Oct;10(7):620-3. No abstract available.

PMID:
22973837
10.

A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV.

Benson CA, van der Horst C, Lamarca A, Haas DW, McDonald CK, Steinhart CR, Rublein J, Quinn JB, Mondou E, Rousseau F; FTC-303/350 Writing Group.

AIDS. 2004 Nov 19;18(17):2269-76.

PMID:
15577539
11.

Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages.

Aquaro S, Svicher V, Ceccherini-Silberstein F, Cenci A, Marcuccilli F, Giannella S, Marcon L, Caliò R, Balzarini J, Perno CF.

J Antimicrob Chemother. 2005 Jun;55(6):872-8. Epub 2005 Apr 21.

PMID:
15845785
12.

Emtricitabine: new preparation. An antiretroviral very similar to lamivudine.

[No authors listed]

Prescrire Int. 2005 Apr;14(76):54-6.

PMID:
15875341
13.

Emtricitabine: an antiretroviral agent for HIV infection.

Bang LM, Scott LJ.

Drugs. 2003;63(22):2413-24; discussion 2425-6. Review.

PMID:
14609348
14.

Synthesis, anti-HIV and antitubercular activities of lamivudine prodrugs.

Sriram D, Yogeeswari P, Gopal G.

Eur J Med Chem. 2005 Dec;40(12):1373-6. Epub 2005 Aug 29.

PMID:
16129516
15.

Emtricitabine/tenofovir disoproxil fumarate: in combination with a protease inhibitor in HIV-1 infection.

Perry CM.

Drugs. 2009;69(7):843-57. doi: 10.2165/00003495-200969070-00005.

PMID:
19441871
16.

Emtricitabine: a new nucleoside analogue for once-daily antiretroviral therapy.

Cahn P.

Expert Opin Investig Drugs. 2004 Jan;13(1):55-68. Review.

PMID:
14680453
17.

[Emtriva (emtricitabine, FTC)].

Kronborg G.

Ugeskr Laeger. 2004 Nov 29;166(49):4458-9. Danish. No abstract available.

PMID:
15626097
18.

Intracellular pharmacology of emtricitabine and tenofovir.

Stevens RC, Blum MR, Rousseau FS, Kearney BP.

Clin Infect Dis. 2004 Sep 15;39(6):877-8; author reply 878-9. No abstract available.

PMID:
15472830
19.

Emtricitabine intolerance in treatment-experienced patients switched from lamivudine: a method of assessing toxicity.

Pollock K, Stebbing J, Bower M, Gazzard B, Nelson M.

J Antimicrob Chemother. 2006 Jul;58(1):227-8. Epub 2006 May 9. No abstract available.

PMID:
16684800
20.

Combination antiretroviral therapy with tenofovir, emtricitabine or lamivudine, and nevirapine.

Redfield RR, Morrow JS.

Clin Infect Dis. 2008 Oct 1;47(7):984-5. doi: 10.1086/591802. No abstract available.

PMID:
18778234

Supplemental Content

Support Center